Early Management of NSTE-ACS: From the ED to the Cath Lab

Slides:



Advertisements
Similar presentations
Unstable angina and NSTEMI
Advertisements

A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.
Listening to the Data: Why There’s Room for Improvement in MI Care Heartscape® Consultants Meeting Charles V. Pollack, Jr, MA, MD, FACEP, FAAEM, FAHA Chairman,
Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Fondaparinux in ACS James Huffman, PGY-3 Emergency Medicine Grand Rounds March 5, 2009.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
OPTIMAL UPSTREAM ANTITHROMBIN THERAPY IN NSTE ACS PATIENTS MANAGED IN THE CARDIAC CATH LAB: DOES IT MATTER WHICH AGENT IS STARTED IN THE ED? Charles V.
Download from Slide 1 AGGRASTAT ® † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT.
Unstable Angina /Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit Adapted from Dr Chris Cannon STRIVE Scientific Committee – 2008 Based.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
Slide 1 AGGRASTAT ™ † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT Phase † Trademarks of Merck & Co., Inc.,
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Pharmacological strategies to reduce periprocedural bleeding
An International Randomized Trial of Early Versus Delayed Invasive Strategies in Patients with Non-ST Segment Elevation Acute Coronary Syndromes TIMACS.
ACS Management NSTEMI Pro DTI “Hook-ster Hoekstra” Pro Factor Xa “Knockdown Diercks”
Clinical Insights, Risk Stratification, and Enhancing Outcomes.
Dr Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield UK Managing bleeding post PCI.
TUESDAY 19TH OCTOBER2010 CATH LAB PRESENTATION. TAO /ACS study STUDY NUMBER: EFC6204 Randomized, double-blind, triple-dummy trial to compare the efficacy.
Enoxaparin – Future Prospects in Cardiovascular Diseases David Hasdai, MD Rabin Medical Center Tel Aviv University.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.
TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients with Acute Coronary Syndrome Undergoing PCI? Frederick Feit, Steven Manoukian, Ramin Ebrahimi,
Cooling Off? Early Intervention? Very Early Intervention? Steve Holmberg Sussex Cardiac Centre.
TIMI 30: The PROTECT Trial High-risk UA/NSTEMI for PCI of a native coronary artery with either DM; or + Troponin; or ST   0.5 mm; or TRS > 3 Bivalirudin.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic.
NICE-3 National Investigators Collaborating on Enoxaparin XXII nd Congress of the European Society of Cardiology August 30, 2000 Amsterdam, The Netherlands.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Intra-procedural Anticoagulation for PCI: Which Drug? How Much? How Long? Michael J. Cowley, FSCAI Nothing to Disclose.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
Northeast Georgia Heart Center Interventional Pharmacology: Anti-thrombin Therapy J. Jeffrey Marshall, MD, FSCAI Past President SCAI, Director.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.
Acute Coronary Syndrome
CPR in ACUTE CORONARY SYNDROM
Cangrelor Case Presentations
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Prospective evaluation of the use of the thrombolysis in myocardial infarction score as a risk stratification tool for chest pain patients admitted to.
T1: ACS Treatment Tutoring
FINESSE: Study Design Acute ST Elevation MI (or New LBBB) within 6h pain onset Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
EARLY ACS Trial Rationale and Design
Antiplatelet Therapy For STEMI: The Case for Cangrelor
Ischaemic Heart Disease Acute Coronary Syndrome
Seeking the Optimal Upstream Therapy for Patients with ACS: Fondaparinux- Low Bleeding Rate and Low Cost Sanjit S. Jolly MD, Interventional Cardiologist,
Preventing Thrombotic Complications in ACS: State of the Art
Hospitalizations in the United States Caused by ACS.
在非ST段抬高的急性冠状动脉综合征(NSTACS) 中早期应用血小板糖蛋白IIbIIIa受体拮抗剂： 一项评估NSTACS治疗中早期应用依替巴肽 临床效果的随机、双盲、安慰剂对照试验 Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation.
The following slides highlight a Hotline presentation at the European Society of Cardiology Congress in Barcelona, Spain, August 29 – September 2, 2009.
Antiplatelet Therapy and Secondary Prevention
A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?
Treatment Options to Consider
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Section F: Clinical guidelines
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
% Heparin + GPI IIb/IIIa Bivalirudin +
Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors with Heparin or LMWH: Results.
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
BRIGHT Trial design: Patients undergoing PCI for ACS were randomized in a 1:1:1 fashion to receive either bivalirudin alone, unfractionated heparin (UFH)
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients
Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

Early Management of NSTE-ACS: From the ED to the Cath Lab

Main Limitations of UFH

Fondaparinux*

Bivalirudin

Otamixaban

Early Management of NSTE-ACS: From the ED to the Cath Lab

Evaluation of Chest Pain

ACCF/AHA Recommendations for Initial Management of UA/NSTEMI

ESSENCE: TIMI Risk Score and Treatment Effect

TIMACS: Early vs Delayed Intervention Stratified by GRACE Score

SYNERGY: Postrandomization Crossover From Enoxaparin to Unfractionated Heparin

Otamixaban: In Clinical Development for Management of ACS

SEPIA-ACS TIMI 42: Otamixaban vs UFH + Eptifibatide in High-Risk NSTEMI ACS

TAO: Study Design

References

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.